<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080206</url>
  </required_header>
  <id_info>
    <org_study_id>188-0551-204</org_study_id>
    <nct_id>NCT04080206</nct_id>
  </id_info>
  <brief_title>A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis</brief_title>
  <official_title>An Open Label, Comparative Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of 188-0551 Spray Versus Reference Listed Drug (RLD) Applied Every 12 Hours for 2 Weeks in Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adrenal suppression effects of corticosteroids are among the most important safety concerns
      for this group of products. This study is to determine and compare the adrenal suppression
      potential and the pharmacokinetic (PK) properties of 188-0551 Spray versus an FDA-approved
      drug (also known as a &quot;Reference Listed Drug&quot; [RLD]) under maximal use conditions when
      applied twice daily (approximately every 12 hours) in adult subjects with stable, moderate to
      severe, plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects to exhibit adrenal suppression as measured by a cortrosyn stimulation test</measure>
    <time_frame>Day 15</time_frame>
    <description>A subject is considered to have adrenal suppression evidence if post stimulation lab draw result is ≤ 18 µg/dL (497 nmol/L).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>188-0551 Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational Topical Spray Product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Listed Drug (RLD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA Approved Topical Cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>188-0551 Spray</intervention_name>
    <description>Applied topically twice daily for two weeks</description>
    <arm_group_label>188-0551 Spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLD</intervention_name>
    <description>Applied topically twice daily for two weeks</description>
    <arm_group_label>Reference Listed Drug (RLD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a male or non-pregnant female and is at least 18 years of age at the time
             of informed consent.

          -  Subject has provided written informed consent.

          -  Subject has moderate or severe psoriasis involving a minimum of 20% Body Surface Area
             (BSA).

          -  Subject has an Investigator's Global Assessment (IGA) score of at least three (3 =
             moderate) at the Baseline Visit.

        Exclusion Criteria:

          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.

          -  Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.

          -  Subject has a physical condition which, in the investigator's opinion, might impair
             evaluation of plaque psoriasis, adrenal axis function or which exposes the subject to
             an unacceptable risk by study participation.

          -  Subject has had prolonged exposure to natural or artificial sources of ultraviolet
             radiation.

          -  Subject is currently enrolled in an investigational drug or device study.

          -  Subject has clinically significant abnormal labs at Visit 1/Screening that precludes
             topical steroid use, in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>TI Clinical Operations</last_name>
    <phone>858-571-1800</phone>
    <phone_ext>147</phone_ext>
    <email>clinicalresearch@therapeuticsinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TI Site #13</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-571-1800</phone>
      <phone_ext>147</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>TI Site #12</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-571-1800</phone>
      <phone_ext>147</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>TI Site #11</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-571-1800</phone>
      <phone_ext>147</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>TI Site #31</name>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-571-1800</phone>
      <phone_ext>147</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>TI Site #32</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-571-1800</phone>
      <phone_ext>147</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>TI Site #23</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-571-1800</phone>
      <phone_ext>147</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>TI Site #22</name>
      <address>
        <city>Rivne</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-571-1800</phone>
      <phone_ext>147</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>TI Site #21</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-571-1800</phone>
      <phone_ext>147</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

